Summary | |
---|---|
Symbol | MUC1 |
Name | mucin 1, cell surface associated |
Aliases | CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ...... |
Chromosomal Location | 1q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Apical cell membrane Single-pass type I membrane protein Note=Exclusively located in the apical domain of the plasma membrane of highly polarized epithelial cells. After endocytosis, internalized and recycled to the cell membrane. Located to microvilli and to the tips of long filopodial protusions.; SUBCELLULAR LOCATION: Isoform 5: Secreted.; SUBCELLULAR LOCATION: Isoform Y: Secreted.; SUBCELLULAR LOCATION: Isoform 9: Secreted.; SUBCELLULAR LOCATION: Mucin-1 subunit beta: Cell membrane. Cytoplasm. Nucleus. Note=On EGF and PDGFRB stimulation, transported to the nucleus through interaction with CTNNB1, a process which is stimulated by phosphorylation. On HRG stimulation, colocalizes with JUP/gamma-catenin at the nucleus. |
Domain |
PF01390 SEA domain |
Function |
The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack.; FUNCTION: The beta subunit contains a C-terminal domain which is involved in cell signaling, through phosphorylations and protein-protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B pathways. In activated T-cells, influences directly or indirectly the Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. Binds, together with KLF4, the PE21 promoter element of TP53 and represses TP53 activity. |
Biological Process |
GO:0000075 cell cycle checkpoint GO:0000077 DNA damage checkpoint GO:0000082 G1/S transition of mitotic cell cycle GO:0006473 protein acetylation GO:0006475 internal protein amino acid acetylation GO:0006486 protein glycosylation GO:0006493 protein O-linked glycosylation GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006978 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0007050 cell cycle arrest GO:0007093 mitotic cell cycle checkpoint GO:0007162 negative regulation of cell adhesion GO:0007346 regulation of mitotic cell cycle GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage GO:0009100 glycoprotein metabolic process GO:0009101 glycoprotein biosynthetic process GO:0010944 negative regulation of transcription by competitive promoter binding GO:0010948 negative regulation of cell cycle process GO:0016266 O-glycan processing GO:0016570 histone modification GO:0016573 histone acetylation GO:0018205 peptidyl-lysine modification GO:0018393 internal peptidyl-lysine acetylation GO:0018394 peptidyl-lysine acetylation GO:0030330 DNA damage response, signal transduction by p53 class mediator GO:0031056 regulation of histone modification GO:0031058 positive regulation of histone modification GO:0031570 DNA integrity checkpoint GO:0031571 mitotic G1 DNA damage checkpoint GO:0033627 cell adhesion mediated by integrin GO:0033628 regulation of cell adhesion mediated by integrin GO:0033629 negative regulation of cell adhesion mediated by integrin GO:0035065 regulation of histone acetylation GO:0035066 positive regulation of histone acetylation GO:0036003 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0042770 signal transduction in response to DNA damage GO:0042771 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042772 DNA damage response, signal transduction resulting in transcription GO:0043413 macromolecule glycosylation GO:0043543 protein acylation GO:0043618 regulation of transcription from RNA polymerase II promoter in response to stress GO:0043620 regulation of DNA-templated transcription in response to stress GO:0043967 histone H4 acetylation GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044773 mitotic DNA damage checkpoint GO:0044774 mitotic DNA integrity checkpoint GO:0044783 G1 DNA damage checkpoint GO:0044819 mitotic G1/S transition checkpoint GO:0044843 cell cycle G1/S phase transition GO:0045786 negative regulation of cell cycle GO:0045787 positive regulation of cell cycle GO:0045930 negative regulation of mitotic cell cycle GO:0070085 glycosylation GO:0071156 regulation of cell cycle arrest GO:0071158 positive regulation of cell cycle arrest GO:0072331 signal transduction by p53 class mediator GO:0072332 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072395 signal transduction involved in cell cycle checkpoint GO:0072401 signal transduction involved in DNA integrity checkpoint GO:0072413 signal transduction involved in mitotic cell cycle checkpoint GO:0072422 signal transduction involved in DNA damage checkpoint GO:0072431 signal transduction involved in mitotic G1 DNA damage checkpoint GO:0090068 positive regulation of cell cycle process GO:0090239 regulation of histone H4 acetylation GO:0090240 positive regulation of histone H4 acetylation GO:0097193 intrinsic apoptotic signaling pathway GO:1901796 regulation of signal transduction by p53 class mediator GO:1901797 negative regulation of signal transduction by p53 class mediator GO:1901983 regulation of protein acetylation GO:1901985 positive regulation of protein acetylation GO:1901987 regulation of cell cycle phase transition GO:1901988 negative regulation of cell cycle phase transition GO:1901990 regulation of mitotic cell cycle phase transition GO:1901991 negative regulation of mitotic cell cycle phase transition GO:1902165 regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:1902166 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:1902229 regulation of intrinsic apoptotic signaling pathway in response to DNA damage GO:1902230 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage GO:1902253 regulation of intrinsic apoptotic signaling pathway by p53 class mediator GO:1902254 negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator GO:1902275 regulation of chromatin organization GO:1902400 intracellular signal transduction involved in G1 DNA damage checkpoint GO:1902402 signal transduction involved in mitotic DNA damage checkpoint GO:1902403 signal transduction involved in mitotic DNA integrity checkpoint GO:1902532 negative regulation of intracellular signal transduction GO:1902806 regulation of cell cycle G1/S phase transition GO:1902807 negative regulation of cell cycle G1/S phase transition GO:1905269 positive regulation of chromatin organization GO:2000045 regulation of G1/S transition of mitotic cell cycle GO:2000134 negative regulation of G1/S transition of mitotic cell cycle GO:2000756 regulation of peptidyl-lysine acetylation GO:2000758 positive regulation of peptidyl-lysine acetylation GO:2001020 regulation of response to DNA damage stimulus GO:2001021 negative regulation of response to DNA damage stimulus GO:2001233 regulation of apoptotic signaling pathway GO:2001234 negative regulation of apoptotic signaling pathway GO:2001242 regulation of intrinsic apoptotic signaling pathway GO:2001243 negative regulation of intrinsic apoptotic signaling pathway |
Molecular Function |
GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000987 core promoter proximal region sequence-specific DNA binding GO:0001159 core promoter proximal region DNA binding GO:0002039 p53 binding |
Cellular Component |
GO:0000785 chromatin GO:0000790 nuclear chromatin GO:0005796 Golgi lumen GO:0016324 apical plasma membrane GO:0044454 nuclear chromosome part GO:0045177 apical part of cell |
KEGG | - |
Reactome |
R-HSA-5621481: C-type lectin receptors (CLRs) R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-5621480: Dectin-2 family R-HSA-5083632: Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) R-HSA-5083636: Defective GALNT12 causes colorectal cancer 1 (CRCS1) R-HSA-5083625: Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC) R-HSA-1643685: Disease R-HSA-3906995: Diseases associated with O-glycosylation of proteins R-HSA-3781865: Diseases of glycosylation R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-6785807: Interleukin-4 and 13 signaling R-HSA-392499: Metabolism of proteins R-HSA-5173105: O-linked glycosylation R-HSA-913709: O-linked glycosylation of mucins R-HSA-597592: Post-translational protein modification R-HSA-449147: Signaling by Interleukins R-HSA-977068: Termination of O-glycan biosynthesis |
Summary | |
---|---|
Symbol | MUC1 |
Name | mucin 1, cell surface associated |
Aliases | CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ...... |
Chromosomal Location | 1q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between MUC1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between MUC1 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | MUC1 |
Name | mucin 1, cell surface associated |
Aliases | CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ...... |
Chromosomal Location | 1q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of MUC1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | MUC1 |
Name | mucin 1, cell surface associated |
Aliases | CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ...... |
Chromosomal Location | 1q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of MUC1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of MUC1 in various data sets.
|
Summary | |
---|---|
Symbol | MUC1 |
Name | mucin 1, cell surface associated |
Aliases | CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ...... |
Chromosomal Location | 1q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MUC1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | MUC1 |
Name | mucin 1, cell surface associated |
Aliases | CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ...... |
Chromosomal Location | 1q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MUC1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MUC1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | MUC1 |
Name | mucin 1, cell surface associated |
Aliases | CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ...... |
Chromosomal Location | 1q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MUC1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | MUC1 |
Name | mucin 1, cell surface associated |
Aliases | CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ...... |
Chromosomal Location | 1q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of MUC1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | MUC1 |
Name | mucin 1, cell surface associated |
Aliases | CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ...... |
Chromosomal Location | 1q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between MUC1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | MUC1 |
Name | mucin 1, cell surface associated |
Aliases | CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ...... |
Chromosomal Location | 1q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting MUC1 collected from DrugBank database. |
There is no record. |